Institution
VU University Medical Center
Healthcare•Amsterdam, Noord-Holland, Netherlands•
About: VU University Medical Center is a healthcare organization based out in Amsterdam, Noord-Holland, Netherlands. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 10882 authors who have published 22907 publications receiving 1156378 citations. The organization is also known as: VUmc.
Topics: Population, Randomized controlled trial, Cancer, Anxiety, Dementia
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is shown that high-fiber feeding in mice improved oral tolerance and protected against food allergy by enhancing retinal dehydrogenase activity in CD103(+) DC, and depended on vitamin A in the diet.
419 citations
••
TL;DR: The aim of this study was to determine the cumulative risk of developing cancer in a large series of MSH6 mutation carriers, and recommended starting colonoscopic surveillance in female MSH 6 mutation carriers from age 30 years.
419 citations
••
TL;DR: Resection and tumescentliposuction seem to be preferable above ultrasound-assisted liposuction for tissue-engineering purposes, and ASC demonstrated chondrogenic and osteogenic differentiation potential.
419 citations
••
Boston University1, University of Melbourne2, Swinburne University of Technology3, University of Savoy4, Rosalind Franklin University of Medicine and Science5, University of Illinois at Chicago6, University of New Brunswick7, Claude Bernard University Lyon 18, University of Amsterdam9, University of Newcastle10, University of British Columbia11, Fordham University12, University of Padua13, McGill University14, Saint Louis University15, University of Waterloo16, George Mason University17, University of Florence18, VU University Medical Center19, University of Michigan20, Harvard University21
TL;DR: The validation of the Obsessive Beliefs Questionnaire (OBQ) and Interpretations of Intrusions Inventory (III) developed by the OCD Cognitions Working Group (OCCWG) to assess the primary beliefs and appraisals considered critical to the pathogenesis of obsessions was reported in this paper.
419 citations
••
TL;DR: Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the disease course are a strong risk factor for long-term MS activity and progression.
Abstract: Importance It remains unclear whether vitamin D insufficiency, which is common in individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes. Objectives To determine whether serum concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, predict disease activity and prognosis in patients with a first event suggestive of MS (clinically isolated syndrome). Design, Setting, and Participants The Betaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment study was a randomized trial originally designed to evaluate the impact of early vs delayed interferon beta-1b treatment in patients with clinically isolated syndrome. Serum 25(OH)D concentrations were measured at baseline and 6, 12, and 24 months. A total of 465 of the 468 patients randomized had at least 1 25(OH)D measurement, and 334 patients had them at both the 6- and 12-month (seasonally asynchronous) measurements. Patients were followed up for 5 years clinically and by magnetic resonance imaging. Main Outcomes and Measures New active lesions, increased T2 lesion volume, and brain volume on magnetic resonance imaging, as well as MS relapses and disability (Expanded Disability Status Scale score). Results Higher 25(OH)D levels predicted reduced MS activity and a slower rate of progression. A 50-nmol/L (20-ng/mL) increment in average serum 25(OH)D levels within the first 12 months predicted a 57% lower rate of new active lesions ( P P = .03), 25% lower yearly increase in T2 lesion volume ( P P = .07) from months 12 to 60. Similar associations were found between 25(OH)D measured up to 12 months and MS activity or progression from months 24 to 60. In analyses using dichotomous 25(OH)D levels, values greater than or equal to 50 nmol/L (20 ng/mL) at up to 12 months predicted lower disability (Expanded Disability Status Scale score, −0.17; P = .004) during the subsequent 4 years. Conclusions and Relevance Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the disease course are a strong risk factor for long-term MS activity and progression.
418 citations
Authors
Showing all 10902 results
Name | H-index | Papers | Citations |
---|---|---|---|
John Q. Trojanowski | 226 | 1467 | 213948 |
Dorret I. Boomsma | 176 | 1507 | 136353 |
Brenda W.J.H. Penninx | 170 | 1139 | 119082 |
Michael John Owen | 160 | 1110 | 135795 |
Lex M. Bouter | 158 | 767 | 103034 |
Frederik Barkhof | 154 | 1449 | 104982 |
Ichiro Kawachi | 149 | 1216 | 90282 |
Walter Paulus | 149 | 809 | 86252 |
Philip Scheltens | 140 | 1175 | 107312 |
Herbert Y. Meltzer | 137 | 1148 | 81371 |
Pim Cuijpers | 136 | 982 | 69370 |
Jeffrey S. Flier | 131 | 314 | 78430 |
Peter Tugwell | 129 | 948 | 125480 |
Gonneke Willemsen | 129 | 575 | 76976 |
Chris J.L.M. Meijer | 128 | 733 | 78705 |